PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 118 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2021. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $209,000 | -19.0% | 29,815 | +6.1% | 0.00% | -25.0% |
| Q2 2021 | $258,000 | -31.2% | 28,105 | -27.1% | 0.00% | -33.3% |
| Q1 2021 | $375,000 | -3.1% | 38,549 | +2.1% | 0.01% | 0.0% |
| Q4 2020 | $387,000 | +4.0% | 37,748 | +2.4% | 0.01% | -14.3% |
| Q3 2020 | $372,000 | +38.3% | 36,851 | +43.0% | 0.01% | +16.7% |
| Q2 2020 | $269,000 | +86.8% | 25,769 | +51.4% | 0.01% | +50.0% |
| Q1 2020 | $144,000 | +65.5% | 17,015 | +71.8% | 0.00% | +100.0% |
| Q4 2019 | $87,000 | -14.7% | 9,905 | +4.0% | 0.00% | 0.0% |
| Q3 2019 | $102,000 | +18.6% | 9,521 | +40.3% | 0.00% | 0.0% |
| Q2 2019 | $86,000 | -65.7% | 6,784 | +4.7% | 0.00% | -66.7% |
| Q1 2019 | $251,000 | +146.1% | 6,477 | +28.9% | 0.01% | +100.0% |
| Q4 2018 | $102,000 | -52.1% | 5,023 | +7.9% | 0.00% | -40.0% |
| Q3 2018 | $213,000 | +634.5% | 4,656 | +1832.0% | 0.01% | +400.0% |
| Q3 2017 | $29,000 | +20.8% | 241 | -11.7% | 0.00% | 0.0% |
| Q2 2017 | $24,000 | +50.0% | 273 | -35.5% | 0.00% | – |
| Q1 2017 | $16,000 | – | 423 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
| Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
| CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
| BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
| WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
| TOBAM | 318,384 | $23,994,000 | 0.94% |
| Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
| Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
| CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |